Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single‐Dose, Open‐Label, Randomized, Four‐Sequence, Four‐Period, Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability of Single Doses of Clobazam Oral Soluble Film (COSF) with Clobazam Tablets (CTAB)

Trial Profile

A Single‐Dose, Open‐Label, Randomized, Four‐Sequence, Four‐Period, Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability of Single Doses of Clobazam Oral Soluble Film (COSF) with Clobazam Tablets (CTAB)

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Clobazam (Primary) ; Clobazam
  • Indications Lennox-Gastaut syndrome
  • Focus Pharmacokinetics; Registrational
  • Sponsors Aquestive Therapeutics
  • Most Recent Events

    • 20 Dec 2018 According to an Aquestive Therapeutics media release, the data was presented at the American Epilepsy Society 2018 Annual Meeting in early December.
    • 02 Nov 2018 According to an Aquestive Therapeutics media release, the U.S. Food and Drug Administration (FDA) approved SYMPAZAN (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
    • 24 Oct 2018 According to results published in the Epilepsia Journal, clobazam oral soluble film (COSF) at single doses of 10 and 20 mg was bioequivalent to clobazam tablets (CTAB) at equivalent doses for both clobazam and its active metabolite N-desmethylclobazam.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top